Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Melanoma Patients
100%
Response Predictors
100%
Pembrolizumab
100%
Fluorothymidine
100%
Positron Emission Tomography/computed Tomography (PET/CT)
75%
SUVmax
50%
Liver
37%
Tumor Volume
37%
Bone Marrow
25%
Response Evaluation Criteria in Solid Tumors (RECIST)
25%
Immune Response Evaluation
25%
Metastatic Melanoma
12%
Spleen
12%
Progressive Disease
12%
Stable Disease
12%
Partial Response
12%
Treatment Response
12%
Complete Response
12%
Tumor Proliferation
12%
Non-responders
12%
Cohen's kappa
12%
Early Predictors
12%
CT Parameters
12%
Tumor Response Evaluation
12%
18F-fluorothymidine
12%
SUVmean
12%
Stage IV Melanoma
12%
Kappa Agreement
12%
SUVpeak
12%
Total Lesion Proliferation
12%
PET Response Criteria in Solid Tumors
12%
Change from Baseline
12%
Single Institution
12%
Anti-PD-1 Immunotherapy
12%
Delta Parameters
12%
Medicine and Dentistry
Positron Emission Tomography-Computed Tomography
100%
Pembrolizumab
100%
Polyethylene Terephthalate
100%
Melanoma
100%
Neoplasm
50%
Response Evaluation Criteria in Solid Tumors
33%
Progressive Disease
16%
Tumor Progression
16%
Fluorine-18
16%
Solid Malignant Neoplasm
16%
Treatment Response
16%
Metastatic Melanoma
16%
Immunotherapy
16%
Diseases
16%
Immunology and Microbiology
Positron Emission Tomography-Computed Tomography
100%
Pembrolizumab
100%
Tumor Volume
50%
Immune Response
33%
Immunotherapy
16%